CellaVision Initiates Marketing of its Analyzers into the Japanese Market

CellaVision has been given official approval for marketing the company's analyzers CellaVision® DM in Japan. The products will be marketed and sold by CellaVison's newly established subsidiary in Japan, CellaVision Japan K.K.

- The establishment of our Japanese subsidiary is advancing according to plan and it is satisfying to now be active on the Japanese market. We hope to be completely operative before the end of the year, says CellaVision's CEO Yvonne Mårtensson.

Japan is the world's second largest market with around 9000 hospitals and 900 commercial laboratories, and has large potential for medical technology products in general. CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids. will primarily focus on the approximately 1000 larger hospital and commercial laboratories benefitting the most from automating their processes.

Read the full press release.

Read also the article in Biotech Scandinavia.

Source: Press release, CellaVision, 03.09.2008